Breaking News

Sunshine Acquires Remaining Rights to Adva-27a

December 29, 2015

Anticancer compound shows potential in pancreatic cancer, breast cancer, small-cell lung cancer and uterine sarcoma

Sunshine Biopharma has acquired all of the remaining rights to its anticancer compound Adva-27a for $12.8 million, which will be paid with quarterly payments through December 2020. The Patent Purchase Agreement provides direct ownership of all issued and pending Adva-27a related patents and intellectual property worldwide. Sunshine previously had ownership of only the U.S. patent.
 
Adva-27a is a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing pancreatic cancer cells, multidrug resistant breast cancer cells, small-cell lung cancer cells and uterine sarcoma cells. Adva-27a is currently in the IND-Enabling stage of development, with plans for Phase I trials in pancreatic cancer and multidrug resistant breast cancer.
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer